Tracer library / [177Lu]Lu-oxodotreotide
[177Lu]Lu-oxodotreotide
Also written as Lu-177-Oxodotreotide; [Lu-177]Lu-oxodotreotide
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 0
What it is
- Compound class
- somatostatin analogue peptide radiopharmaceutical (oxodotreotide)
- Target / mechanism
- —
- Clinical application
- Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours PMID 36358631
- Theranostic pair
- —
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Investigation of MicroRNAs as predictors of radioligand therapy response in gastroenteropancreatic neuroendocrine tumours.2026 · Sci Rep · Clinical study
- Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.2026 · Ann Nucl Med · Clinical study · Phase I/II
- 177Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods.2024 · Eur J Hosp Pharm · Clinical study
- Amino Acid Solutions for 177Lu-Oxodotreotide Premedication: A Tolerance Study.2022 · Cancers (Basel) · Clinical study
- Three Cases of Merkel Cell Carcinoma Treated With Lutetium-177 Oxodotreotide.2026 · J Dermatol · Case report
Need this precursor?We can point you to suppliers for [177Lu]Lu-oxodotreotide, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.